《大行》高盛維持百濟神州(ONC.US)「買入」評級 目標價升至389.23美元
高盛發表研究報告指,百濟神州(06160.HK)(ONC.US)與Royalty Pharma(RPRX.US)達成高達9.5億美元特許權合作,授出單克隆抗體Imdelltra(tarlatamab)在中國以外地區特許權使用,百濟神州可獲8.85億美元預付款、高達6,500萬美元剩餘特許權出售選擇權,以及超過15億美元部分特許權分成。
雖然僅預付款將於交易完成時收取,但高盛認為百濟神州極有可能獲得另外兩部分付款。該產品去年5月獲美國FDA批准作為首創DLL3靶向療法,該行預期,tarlatamab今年上半年銷售額達2.15億美元,預料全年將增長至逾5億美元,相應將公司2025至2027年每股盈利預測從2.77、6.61及8.04美元,調整為8.94、6.64及7.32美元,維持「買入」評級,美股目標價從378.2美元上調至389.23美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.